Generated by AI
MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases. The company’s current programs center on obesity and metabolic dysfunction-associated steatohepatitis (MASH), with an emphasis on drug candidates designed to address metabolic regulation, appetite control, and related disease pathways. MetaVia’s pipeline also includes research in type 2 diabetes and other cardiometabolic conditions, reflecting its broader focus on diseases linked to metabolic dysfunction. Based in Cambridge, Massachusetts, MetaVia operates in the biopharmaceutical sector, where its role is to advance early- and mid-stage drug development through clinical testing and therapeutic innovation.
Website545 Concord Avenue
Cambridge, MA, 02138
United States
The latest articles about MTVA.
Detailed price information for Metavia Inc (MTVA-Q) from The Globe and Mail including charting and trades.
Summary of Jun 9's posts. Generated by AI.
Summary of May 22's posts. Generated by AI.
No summary yet.
Summary of Jun 6's posts. Generated by AI.
Investors talking about MTVA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.